title: [Osmo-adalat in the treatment of isolated systolic and systolic-diastolic arterial hypertension in aged patients].
abstract: OBJECTIVE
  To examine efficiency and tolerance of osmo-adalat in monotherapy of mild and moderate arterial hypertension (AH) in the elderly.
  
  
  METHODS
  60 AH patients were randomized into two groups. Group 1 received osmo-adalat monotherapy in daily dose 30 mg for 3 weeks. These were 14 patients with isolated systolic AH (ISAH) and 16 patients with essential hypertension (EH). Of group 2 patients, 15 with ISAH and 15 with EH received cordipin in a dose 10 mg three times a day. All the patients underwent 24-h monitoring of arterial pressure, in 18 patients arterial pressure and ECG were registered in parallel for 24 hours.
  
  
  RESULTS
  AH treatment with osmo-adalat is rather effective. This is proved by its positive effect on shifted profile of arterial pressure in patients with ISAH and EH. A fall of arterial pressure on the peak of osmo-adalat antihypertensive action is not associated with hypotonic overloading of target organs, myocardial ischemia and increased heart rate. A single intake of osmo-adalat provides a smooth circadian control of arterial pressure in elderly hypertensive patients, the end effect being 50% of the peak one. The drug is well tolerated. Side effects do not require osmo-adalat discontinuation.
  
  
  CONCLUSIONS
  Osmo-adalat in a single daily dose 30 mg is effective and safe in the treatment of mild and moderate AH in elderly patients.
authors.forename: B I
authors.initials: BI
authors.lastname: Gel'tser
authors.forename: V N
authors.initials: VN
authors.lastname: Kotel'nikov
authors.forename: M V
authors.initials: MV
authors.lastname: Varnina
mesh_terms: D000367:Age Factors; D000368:Aged; D002121:Calcium Channel Blockers / Q000008:administration & dosage / Q000627:therapeutic use*; D002940:Circadian Rhythm; D003971:Diastole; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D008962:Models, Theoretical; D008991:Monitoring, Physiologic; D009543:Nifedipine / Q000008:administration & dosage / Q000627:therapeutic use*; D013599:Systole; D013997:Time Factors
chemical_list: D002121:Calcium Channel Blockers; D009543:Nifedipine